Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

40%

2 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 3
2(40.0%)
Phase 2
1(20.0%)
Early Phase 1
1(20.0%)
Phase 1
1(20.0%)
5Total
Phase 3(2)
Phase 2(1)
Early Phase 1(1)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT03050476Phase 2Recruiting

Preventing Systemic Inflammation After Cardiac Surgery With Alkaline Phosphatase

Role: lead

NCT01144611Phase 3Completed

Efficacy and Safety of Bovine Intestinal Alkaline Phosphatase (bIAP) During Heart Surgery

Role: lead

NCT01416493Phase 1Completed

Bovine Intestinal Alkaline Phosphatase (bIAP) Modulating Rheumatoid Arthritis

Role: lead

NCT01889147Early Phase 1Completed

Microdose and First-In-Human (FIH) Study of Recombinant Human Placental Alkaline Phosphatase (hRESCAP)

Role: collaborator

NCT01010724Phase 3Completed

Efficacy and Safety Study on bIAP

Role: collaborator

All 5 trials loaded